Stockreport

LB Pharmaceuticals initiates Phase 2 trial of LB-102 [Yahoo! Finance]

LB Pharmaceuticals Inc  (LBRX) 
PDF LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potentia [Read more]